MATERIALS AND METHODS
For these experiments, adult male Sprague Dawley rats (average wet weight: 250 gm) were sacrificed in groups of 5 to 10 and posterior pituitaries (mean wet weight: 1.6 LO.1 mg) and substantia nigra (mean wet weight: 10.5 0.2 mg) were pooled. Experiments were done in triplicate. The tissues were extracted in 10 volumes of acetone: 0.1 N HCl (3:l) as described previously (5) . The extracts were concentrated and redissolyed in 500 1 of 10% formic acid buffer and fractionated by gel filtration on a Sephadex G-50 column ( 1 x 54 cm; Pharmacia) equilibrated in 10% formic acid which contained 100 pg/ml bovine serum albumin. The column was eluted with a flow rate of 1.5 ml/hr and 600 pl fractions were collected. The void volume was marked with bovine serum albumin and the total volume was marked with 2, B-mercaptoethanol. Following gel filtration, aliquots of fractions were concentrated under vacuum (Savant) and analyzed by radioimmunoassay. Recoveries averaged 82%.
Several radioimmunoassays to various end products of pro-dynorphin were used in this study. Radioimmunoassays specific for dynorphin A(l-17), dynorphin A(l-8), dynorphin B, and o-neo-endorphin were done as described by Cone et al. (4) . The specificities and sensitivities of these antisera are described in Dores et @.
(5). Antis erum against synthetic porcine bridge peptide(l-21) (1) was generated in rabbits and was used at a final dilution of 1:15,000, with an average midpoint of 75 fmol/tube.
In order to assay each column run for all the potential pro-dynorphin-related products, the following fractions were assayed: for dynorphin A(l-17), #42-50; for dynorphin A(l-8), 852-60; for dynorphin B, f/48-53; for a-neo-endorphin, 150-55; and for bridge peptide, 642-50.
RESULTS AND DISCUSSION
The results of analyses of extracts of rat posterior pituitary are summarized in Fig. 1 and Table 1 . Dynorphin A(l-17)-sized material and dynorphin A(l-8)-sized material represented the major forms of dynorphin A in these extracts. On the average the molar ratio of dynorphin A(l-17) to dynorphin A(l-8) in this terminal field was 1:2. These results are in general agreement with previous studies on this terminal field (2, 3, 4) . As shown in Table 1 , the levels of bridge peptide-sized material are approximately equimolar with both dynorphin A and a-neo-endorphin; thus, it appears that this polypeptide is a major nonopioid end product of pro-dynorphin post-translational processing in this terminal field. By contrast, the levels of dynorphin B-sized material were 50% lower than Dynorphin A levels.
Analyses of rat substantia nigra extracts are summarized in Fig. 2 and Table 1 . As seen in the posterior pituitary, the levels of dynorphin A, o-neo-endorphin, and bridge peptide were equimolar. A striking feature of the substantia nigra is the low levels of dynorphin A(l-17)-related material (Fig. 2) . In this terminal field the major dynorphin A product is dynorphin A(l-8) which is present in a 16 fold higher molar concentration than dynorphin A(l-17). Thus, dynorphin A(l-17) appears to function as a biosynthetic intermediate, rather than an end product. The levels of dynorphin B, while higher than dynorphin A(l-17), are on the average 60 % lower than dynorphin A(l-8) or a -neo-endorphin. A recent study has suggested that the opioid 
